Approval Year
Substance Class |
Structurally Diverse
Created
by
admin
on
Edited
Sat Dec 16 05:21:29 UTC 2023
by
admin
on
Sat Dec 16 05:21:29 UTC 2023
|
Source Materials Class | ORGANISM |
Source Materials Type | MAMMAL |
Source Materials Parent | |
Part | BLOOD SERUM |
Fraction Name | SERA IMMUNOGLOBULIN IGG |
Record UNII |
D7RD81HE4W
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
308710
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
||
|
NDF-RT |
N0000184163
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
||
|
FDA ORPHAN DRUG |
182503
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
||
|
FDA ORPHAN DRUG |
136800
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
||
|
WHO-VATC |
QL04AA04
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
||
|
FDA ORPHAN DRUG |
64491
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
||
|
FDA ORPHAN DRUG |
301810
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
||
|
FDA ORPHAN DRUG |
226006
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
||
|
FDA ORPHAN DRUG |
838821
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
||
|
NCI_THESAURUS |
C2701
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
||
|
WHO-ATC |
L04AA04
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C80833
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
PRIMARY | |||
|
SUB128808
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
PRIMARY | |||
|
DB00098
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
PRIMARY | |||
|
N0000178327
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
PRIMARY | Lymphocyte Function Alteration [PE] | ||
|
308067-60-9
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
GENERIC (FAMILY) | |||
|
D7RD81HE4W
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
PRIMARY | |||
|
N0000009689
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
PRIMARY | Increased T Lymphocyte Destruction [PE] | ||
|
N0000007920
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
PRIMARY | Immunoglobulins [Chemical/Ingredient] | ||
|
N0000020023
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
PRIMARY | Antibody-Surface Protein Interactions [MoA] | ||
|
D7RD81HE4W
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
PRIMARY | |||
|
C512542
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Agent Modifications
Modification Process | Modification Role | Modification Type | Amount | Fragment Name | Fragment ID |
---|---|---|---|---|---|
TARGETED ANTIGEN | IMMUNOLOGICAL |
|
HUMAN THYMOCYTE, AUTOLOGOUS | J56RKY13OV |